PanTheryx Equity of Access

GI health is a right of every individual on the planet.

We believe that GI health is a right of every individual on the planet, regardless of their background, geographic location, or socioeconomic status. In pursuit of this mission we have made a commitment to launching our products in some of the most challenging developing markets, establishing distribution networks to reach patients in remote and rural regions, and focusing our R&D efforts on under-researched diseases impacting both developed and developing markets.

Equity of Access Initiative

Through The Equity of Access Initiative, PanTheryx partners with non-profit organizations to reach the poorest, neediest children and make sure they have access to treatment.

The Equity of Access Initiative ensures distribution of our products to rural and other low-income populations who are most susceptible to disease and educate community health workers in the prevention and treatment of disease for children in need. We measure the impact of the program on the communities we serve by tracking key quality of life indicators such as reductions in antibiotic use, hospitalization rates, need for stepped-up care and intravenous rehydration, and episode duration.

Equitable access does not only mean treatment accessibility at PanTheryx. Through the EAI, we work with partners to train community health workers on prevention and treatment, as well as, set up programs to track and monitor the program’s impact on quality of life among children in the community.

Our partnership with Project Cure in Mexico will distribute more than 300,000 sachets of our lead product.

We are also committed to expanding healthcare access by researching and investing in solutions for underserved diseases that primarily impact developing nations.

Our Equity of Access initiative aims to not only ensure that every individual has equal access to our transformative products, but that we continue to conduct research to address diseases that affect developing nations and the people that live there. Research studies are currently taking place in distinct locations around the world including Guatemala, Russia, Bangladesh, and Pakistan.

Donate Now

PanTheryx Equity of Access

GI health is a right of every individual on the planet.

We believe that GI health is a right of every individual on the planet, regardless of their background, geographic location, or socioeconomic status. In pursuit of this mission we have made a commitment to launching our products in some of the most challenging developing markets, establishing distribution networks to reach patients in remote and rural regions, and focusing our R&D efforts on under-researched diseases impacting both developed and developing markets.

Equity of Access Initiative

Through The Equity of Access Initiative, PanTheryx partners with non-profit organizations to reach the poorest, neediest children and make sure they have access to treatment.

The Equity of Access Initiative ensures distribution of our products to rural and other low-income populations who are most susceptible to disease and educate community health workers in the prevention and treatment of disease for children in need. We measure the impact of the program on the communities we serve by tracking key quality of life indicators such as reductions in antibiotic use, hospitalization rates, need for stepped-up care and intravenous rehydration, and episode duration.

Equitable access does not only mean treatment accessibility at PanTheryx. Through the EAI, we work with partners to train community health workers on prevention and treatment, as well as, set up programs to track and monitor the program’s impact on quality of life among children in the community.

Our partnership with Project Cure in Mexico will distribute more than 300,000 sachets of our lead product.

We are also committed to expanding healthcare access by researching and investing in solutions for underserved diseases that primarily impact developing nations.

Our Equity of Access initiative aims to not only ensure that every individual has equal access to our transformative products, but that we continue to conduct research to address diseases that affect developing nations and the people that live there. Research studies are currently taking place in distinct locations around the world including Guatemala, Russia, Bangladesh, and Pakistan.

Donate Now

One of our products was selected as 1 of the 30 Leading Healthcare Innovations

With great promise to transform global health by 2030 and to help accelerate progress toward United Nations Sustainable Development Goals health target.

Source: Reimagining Global Health, Innovation Countdown 2030 Initiative